Companies › Shanghai Yidian Pharmaceutical Technology Development
3 active drug programs in 6 registered trials: 5 Phase 2, 1 Phase 1; Respiratory, Other, Infectious disease; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| YD0743 | – | Phase 2 | Sepsis | Dec 2026 |
| HL-1186 | – | Phase 2 | Moderate to Severe Acute Postoperative Pain; Postherpetic Neuralgia ( PHN ); Healthy Participants | Jun 2027 |
| HTMC0658 | – | Phase 2 | Chronic Sinusitis Without Nasal Polyps | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06912295 | HL-1186 | Phase 1 | Healthy Participants | Other | Aug 2025 |
| NCT07147049 | HL-1186 | Phase 2 | Moderate to Severe Acute Postoperative Pain | Other | Dec 2025 |
| NCT07311369 | HL-1186 | Phase 2 | Moderate to Severe Acute Postoperative Pain | Other | Feb 2026 |
| NCT07174115 | HTMC0658 | Phase 2 | Chronic Sinusitis Without Nasal Polyps | Respiratory | Apr 2026 |
| NCT07413094 | YD0743 | Phase 2 | Sepsis | Infectious disease | Dec 2026 |
| NCT07758920 | HL-1186 | Phase 2 | Postherpetic Neuralgia ( PHN ) | Other | Jun 2027 |
No annotated target.
–
BioAegis Therapeutics Freya Biosciences ApS Mundipharma Research Shanghai Synvida Biotechnology Aligos Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.